TOL Biotech

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Founded last year and based in San Francisco, Taxo tells TechCrunch it passed $1 million ARR six months after its launch. It now serves about 15 customers, ranging from clinics to government providers.

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the appointment of Dr. Mikael Dolsten to its board of directors.

The market's appetite for AI applications in healthcare is rapidly increasing, with TEM emerging as a top contender in this high-growth sector.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

Telescope Innovations Corp. (CSE:TELI) is leveraging its expertise to advance chemistry process development and crystallization optimization in pharmaceuticals, industrial chemicals, and critical minerals ・Telescope's Self-Driving Labs (SDLs) integrate AI,

Iktos, a global leader in AI-driven drug discovery, has secured a prestigious €2.5 million grant from the European Innovation Council (EIC) Accelerator to advance its AI and robotics synthesis automation technology.

Biotechnology innovations are revolutionizing healthcare with AI, data science, and automation, leading to more precise and personalized treatments.